Table 2.
Prophylactic and therapeutic activity of m2C9, 2C9-H4 cIgG, and 2C9-H4 cIgM in 17D-204-challenged AG129 mice.
| Treatmenta | Survivors/Total Mice (% Survivors) | Brain Viral Loadb | ASTc | |
|---|---|---|---|---|
| Survivors | Dead | |||
| PBS Controls | 1/27 (4) | n.a. | 6.9 (0.6) | 17.3 (4.3) |
| Prophylaxis Day -1 | ||||
| m2C9 IgG | 18/19 (95)d | 1.2 (0.8)e | 7.0 | 30.4 (2.5)d |
| 2C9-H4 IgG | 18/25 (72)d | 0.7 (0.4)e | 6.7 | 28.3 (4.5)d |
| 2C9-H4 IgM | 2/10 (20) | 6.0 (0.1)f | 7.7 (0.3) | 20.6 (5.9) |
| Treatment Day 1 | ||||
| m2C9 IgG | 7/10 (70)d | 2.0 (2.0)e | 7.4 (3.0) | 25.8 (8.8)d |
| 2C9- H4 IgG | 3/15 (20) | 1.7d | 6.7 (0.5) | 19.4 (7.0) |
| Treatment Day 3 | ||||
| m2C9 IgG | 0/10 (0) | n.a. | 6.6 (0.3) | 15.8 (2.8) |
| 2C9-H4 IgG | 0/15 (0) | n.a. | 6.7 4) | 15.3 (2.0) |
a
Mice were inoculated i.p. with 127 μg purified MAb 24 hours pre-infection or 24 or 72 hours post-infection by an i.p. viral challenge.
b
Expressed as mean (s.d.) genomic copies (log10)/g tissue.
c
Experiments were terminated at 31 days post-infection. Average survival time (AST) in days (s.d.).
d
ρ <0.05 by two-tailed t-test statistic vs. PBS control mice.
e
ρ <0.05 by two-tailed t-test statistic vs. paired PBS control mice or paired dead mice.
f
ρ <0.05 by two-tailed t-test statistic vs. paired dead mice only.